Brief: Freeline Presents On Its Fabry And Gaucher Disease AAV-Based Gene Therapies

Freeline Therapeutics Holdings

08/02/2022 12:52

Feb 8 (Reuters) - Freeline Therapeutics Holdings PLC
 FRLN.O :
    * FREELINE PRESENTS ON ITS FABRY AND GAUCHER DISEASE
AAV-BASED
GENE THERAPIES AT THE 18TH ANNUAL WORLDSYMPOSIUM™
    * FREELINE THERAPEUTICS - FLT190 WELL-TOLERATED WITH
PROMISING
EARLY EFFICACY IN FABRY DISEASE INCLUDING SUSTAINED Α-GAL A
EXPRESSION UP TO TWO YEARS
    * FREELINE THERAPEUTICS - GALILEO-1, MULTICENTER PHASE 1/2
CLINICAL TRIAL EVALUATING FLT201 IN GAUCHER DISEASE TYPE 1
INITIATED

Source text for Eikon:  ID:nGNX6MZcq4 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))